Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?

J Eur Acad Dermatol Venereol. 2010 Jun;24(6):737-8. doi: 10.1111/j.1468-3083.2009.03455.x. Epub 2009 Nov 11.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Angiokeratoma / drug therapy*
  • Enzyme Replacement Therapy / methods*
  • Fabry Disease / drug therapy*
  • Humans
  • Isoenzymes / therapeutic use*
  • Male
  • Remission Induction
  • Scrotum
  • Skin Neoplasms / drug therapy*
  • Treatment Outcome
  • alpha-Galactosidase / therapeutic use*

Substances

  • Isoenzymes
  • alpha-Galactosidase
  • agalsidase beta